Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial
Background and aimsDietary regimens are crucial in the management of non-alcoholic fatty liver disease (NAFLD). The effects of intermittent fasting (IF) have gained attention in this regard, but further research is warranted. Thus, we aimed to ascertain the overall effects of the 5:2 IF diet (5 days...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2022.948655/full |
| _version_ | 1818043677535109120 |
|---|---|
| author | Hamed Kord Varkaneh Ammar Salehi sahlabadi Mihnea-Alexandru Găman Mihnea-Alexandru Găman Mohsen Rajabnia Melahat Sedanur Macit-Çelebi Heitor O. Santos Azita Hekmatdoost |
| author_facet | Hamed Kord Varkaneh Ammar Salehi sahlabadi Mihnea-Alexandru Găman Mihnea-Alexandru Găman Mohsen Rajabnia Melahat Sedanur Macit-Çelebi Heitor O. Santos Azita Hekmatdoost |
| author_sort | Hamed Kord Varkaneh |
| collection | DOAJ |
| description | Background and aimsDietary regimens are crucial in the management of non-alcoholic fatty liver disease (NAFLD). The effects of intermittent fasting (IF) have gained attention in this regard, but further research is warranted. Thus, we aimed to ascertain the overall effects of the 5:2 IF diet (5 days a week of normal food intake and 2 consecutive fasting days) in patients with NAFLD compared to a control group (usual diet).Methods and resultsA 12-week randomized controlled trial was performed to evaluate the effects of the 5:2 IF diet on anthropometric indices, body composition, liver indices, serum lipids, glucose metabolism, and inflammatory markers in patients with NAFLD. The IF group (n = 21) decreased body weight (86.65 ± 12.57–82.94 ± 11.60 kg), body mass index (30.42 ± 2.27–29.13 ± 1.95 kg/m2), waist circumference (103.52 ± 6.42–100.52 ± 5.64 cm), fat mass (26.64 ± 5.43–23.85 ± 5.85 kg), fibrosis (6.97 ± 1.94–5.58 ± 1.07 kPa), steatosis scores/CAP (313.09 ± 25.45–289.95 ± 22.36 dB/m), alanine aminotransferase (41.42 ± 20.98–28.38 ± 15.21 U/L), aspartate aminotransferase (34.19 ± 10.88–25.95 ± 7.26 U/L), triglycerides (171.23 ± 39.88–128.04 ± 34.88 mg/dl), high-sensitivity C-reactive protein (2.95 ± 0.62 −2.40 ± 0.64 mg/L), and cytokeratin-18 (1.32 ± 0.06–1.19 ± 0.05 ng/ml) values compared to the baseline and the end of the control group (n = 23)—p ≤ 0.05 were considered as significant. However, the intervention did not change the levels of high-density lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, fasting blood sugar, insulin, HOMA-IR, and total antioxidant capacity.ConclusionAdhering to the 5:2 IF diet can reduce weight loss and related parameters (fat mass and anthropometric indicators of obesity), as well as hepatic steatosis, liver enzymes, triglycerides, and inflammatory biomarkers in patients with NAFLD. |
| first_indexed | 2024-12-10T09:06:01Z |
| format | Article |
| id | doaj.art-097ab402039a4942980fea27466bbcc8 |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-12-10T09:06:01Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-097ab402039a4942980fea27466bbcc82022-12-22T01:55:08ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-07-01910.3389/fnut.2022.948655948655Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trialHamed Kord Varkaneh0Ammar Salehi sahlabadi1Mihnea-Alexandru Găman2Mihnea-Alexandru Găman3Mohsen Rajabnia4Melahat Sedanur Macit-Çelebi5Heitor O. Santos6Azita Hekmatdoost7Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IranFaculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, RomaniaCenter of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, RomaniaGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran, IranDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Ondokuz Mayis University, Samsun, TurkeySchool of Medicine, Federal University of Uberlandia (UFU), Uberlândia, BrazilDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IranBackground and aimsDietary regimens are crucial in the management of non-alcoholic fatty liver disease (NAFLD). The effects of intermittent fasting (IF) have gained attention in this regard, but further research is warranted. Thus, we aimed to ascertain the overall effects of the 5:2 IF diet (5 days a week of normal food intake and 2 consecutive fasting days) in patients with NAFLD compared to a control group (usual diet).Methods and resultsA 12-week randomized controlled trial was performed to evaluate the effects of the 5:2 IF diet on anthropometric indices, body composition, liver indices, serum lipids, glucose metabolism, and inflammatory markers in patients with NAFLD. The IF group (n = 21) decreased body weight (86.65 ± 12.57–82.94 ± 11.60 kg), body mass index (30.42 ± 2.27–29.13 ± 1.95 kg/m2), waist circumference (103.52 ± 6.42–100.52 ± 5.64 cm), fat mass (26.64 ± 5.43–23.85 ± 5.85 kg), fibrosis (6.97 ± 1.94–5.58 ± 1.07 kPa), steatosis scores/CAP (313.09 ± 25.45–289.95 ± 22.36 dB/m), alanine aminotransferase (41.42 ± 20.98–28.38 ± 15.21 U/L), aspartate aminotransferase (34.19 ± 10.88–25.95 ± 7.26 U/L), triglycerides (171.23 ± 39.88–128.04 ± 34.88 mg/dl), high-sensitivity C-reactive protein (2.95 ± 0.62 −2.40 ± 0.64 mg/L), and cytokeratin-18 (1.32 ± 0.06–1.19 ± 0.05 ng/ml) values compared to the baseline and the end of the control group (n = 23)—p ≤ 0.05 were considered as significant. However, the intervention did not change the levels of high-density lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, fasting blood sugar, insulin, HOMA-IR, and total antioxidant capacity.ConclusionAdhering to the 5:2 IF diet can reduce weight loss and related parameters (fat mass and anthropometric indicators of obesity), as well as hepatic steatosis, liver enzymes, triglycerides, and inflammatory biomarkers in patients with NAFLD.https://www.frontiersin.org/articles/10.3389/fnut.2022.948655/fullnon-alcoholic fatty liver diseaseintermittent fasting (5:2)liver enzymestime-restricted eatingfasting |
| spellingShingle | Hamed Kord Varkaneh Ammar Salehi sahlabadi Mihnea-Alexandru Găman Mihnea-Alexandru Găman Mohsen Rajabnia Melahat Sedanur Macit-Çelebi Heitor O. Santos Azita Hekmatdoost Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial Frontiers in Nutrition non-alcoholic fatty liver disease intermittent fasting (5:2) liver enzymes time-restricted eating fasting |
| title | Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial |
| title_full | Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial |
| title_fullStr | Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial |
| title_full_unstemmed | Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial |
| title_short | Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial |
| title_sort | effects of the 5 2 intermittent fasting diet on non alcoholic fatty liver disease a randomized controlled trial |
| topic | non-alcoholic fatty liver disease intermittent fasting (5:2) liver enzymes time-restricted eating fasting |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2022.948655/full |
| work_keys_str_mv | AT hamedkordvarkaneh effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT ammarsalehisahlabadi effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT mihneaalexandrugaman effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT mihneaalexandrugaman effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT mohsenrajabnia effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT melahatsedanurmacitcelebi effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT heitorosantos effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial AT azitahekmatdoost effectsofthe52intermittentfastingdietonnonalcoholicfattyliverdiseasearandomizedcontrolledtrial |